{"id":"act-293987","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug directly activates soluble guanylate cyclase independently of nitric oxide, leading to increased production of cyclic GMP (cGMP), a key second messenger that promotes smooth muscle relaxation and vasodilation. This mechanism is particularly relevant in pulmonary hypertension and fibrotic diseases where impaired NO-sGC-cGMP signaling contributes to pathology.","oneSentence":"ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:44:11.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"},{"name":"Chronic thromboembolic pulmonary hypertension (CTEPH)"}]},"trialDetails":[{"nctId":"NCT04914247","phase":"","title":"Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Actelion","startDate":"","conditions":"Non-healing Wound, Thromboangiitis Obliterans","enrollment":""},{"nctId":"NCT03492177","phase":"PHASE2","title":"A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2018-07-23","conditions":"Pulmonary Arterial Hypertension","enrollment":63},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT07453030","phase":"","title":"Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Caio Júlio César dos Santos Fernandes","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":30},{"nctId":"NCT07356375","phase":"","title":"Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT01106014","phase":"PHASE3","title":"Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":1156},{"nctId":"NCT00993408","phase":"PHASE2","title":"Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-04-30","conditions":"Pulmonary Arterial Hypertension","enrollment":43},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT03187678","phase":"PHASE3","title":"Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-12-04","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT04567602","phase":"","title":"A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2020-10-06","conditions":"Pulmonary Arterial Hypertension","enrollment":372},{"nctId":"NCT03496506","phase":"PHASE1","title":"A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-03-05","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT04565990","phase":"PHASE3","title":"A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study","status":"COMPLETED","sponsor":"Actelion","startDate":"2021-05-03","conditions":"Hypertension, Pulmonary","enrollment":43},{"nctId":"NCT06932198","phase":"PHASE1","title":"Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-01-09","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":14},{"nctId":"NCT04266756","phase":"PHASE1","title":"A Study of Selexipag in Healthy Male Participant","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-01-23","conditions":"Healthy","enrollment":24},{"nctId":"NCT04435782","phase":"PHASE4","title":"A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging","status":"TERMINATED","sponsor":"Actelion","startDate":"2021-07-07","conditions":"Pulmonary Arterial Hypertension","enrollment":9},{"nctId":"NCT03278002","phase":"","title":"A Registry for Patients Taking Uptravi","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-11-01","conditions":"Pulmonary Arterial Hypertension","enrollment":800},{"nctId":"NCT02558231","phase":"PHASE3","title":"The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-05-01","conditions":"Pulmonary Arterial Hypertension","enrollment":247},{"nctId":"NCT01112306","phase":"PHASE3","title":"ACT-293987 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-07-07","conditions":"Pulmonary Arterial Hypertension","enrollment":709},{"nctId":"NCT03078907","phase":"PHASE4","title":"Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-11-08","conditions":"Pulmonary Arterial Hypertension","enrollment":108},{"nctId":"NCT02770222","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT02882425","phase":"PHASE1","title":"Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-01","conditions":"Healthy Subjects","enrollment":19},{"nctId":"NCT02745860","phase":"PHASE1","title":"Comparison of Two Dose Strengths of Selexipag in Healthy Adults","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02206295","phase":"PHASE1","title":"Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-09","conditions":"Bioequivalence","enrollment":80},{"nctId":"NCT02260557","phase":"PHASE2","title":"Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-10","conditions":"Raynaud's Phenomenon Secondary to Systemic Sclerosis","enrollment":74},{"nctId":"NCT06753981","phase":"","title":"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-12-10","conditions":"Arterial Pulmonary Hypertension (PAH)","enrollment":48},{"nctId":"NCT05825417","phase":"PHASE4","title":"Pulmonary Hypertension: Intensification and Personalisation of Combination Rx","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2023-06-14","conditions":"Pulmonary Arterial Hypertension","enrollment":40},{"nctId":"NCT03689244","phase":"PHASE3","title":"A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment","status":"TERMINATED","sponsor":"Actelion","startDate":"2019-01-23","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":128},{"nctId":"NCT03942211","phase":"PHASE2","title":"A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag","status":"TERMINATED","sponsor":"Actelion","startDate":"2021-02-26","conditions":"Sarcoidosis-associated Pulmonary Hypertension","enrollment":10},{"nctId":"NCT05600218","phase":"","title":"RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists","status":"UNKNOWN","sponsor":"Hospital Costa del Sol","startDate":"2021-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":60},{"nctId":"NCT04589390","phase":"PHASE2","title":"Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-15","conditions":"Pulmonary Hypertension, Schistosomiasis","enrollment":20},{"nctId":"NCT04309838","phase":"","title":"Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-03","conditions":"Pulmonary Arterial Hypertension, PAH","enrollment":30},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT02471183","phase":"PHASE3","title":"Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-10-12","conditions":"Pulmonary Arterial Hypertension","enrollment":34},{"nctId":"NCT03016468","phase":"PHASE2","title":"Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-05","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT02791815","phase":"PHASE1","title":"Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-07","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02206204","phase":"PHASE1","title":"Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-06","conditions":"Cardiodynamics, Safety, Tolerability","enrollment":159}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CAESAREAN SECTION"},{"count":2,"reaction":"PREGNANCY OF PARTNER"},{"count":1,"reaction":"ABORTION MISSED"},{"count":1,"reaction":"AMNIOCENTESIS"},{"count":1,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"LIVE BIRTH"},{"count":1,"reaction":"MATERNAL EXPOSURE BEFORE PREGNANCY"},{"count":1,"reaction":"PREGNANCY"},{"count":1,"reaction":"PREMATURE BABY"},{"count":1,"reaction":"UTERINE DILATION AND EVACUATION"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ACT-293987","genericName":"ACT-293987","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis. Used for Pulmonary arterial hypertension (PAH), Chronic thromboembolic pulmonary hypertension (CTEPH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}